Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Clinical Trial Evaluating DCVax-L Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)

Trial Profile

A Phase III Clinical Trial Evaluating DCVax-L Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (GBM)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Brain cancer; Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Northwest Biotherapeutics
  • Most Recent Events

    • 14 Dec 2018 According to a Northwest Biotherapeutics media release, the company is intended to complete this study in 2019.
    • 19 Nov 2018 According to a Northwest Biotherapeutics media release, updated interim data from the study has been presented at the 23rd Annual Meeting of the Society for Neuro-Oncology.
    • 19 Nov 2018 Updated interim data from the study has been presented in the Northwest Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top